Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

245.80
+5.322.21%
Post-market: 245.800.00000.00%19:30 EDT
Volume:422.91K
Turnover:103.85M
Market Cap:15.96B
PE:16.80
High:246.73
Open:244.60
Low:244.04
Close:240.48
52wk High:266.38
52wk Low:123.88
Shares:64.91M
Float Shares:62.69M
Volume Ratio:0.77
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.32
PE(LYR):-42.09

Loading ...

Jazz Pharmaceuticals Sees Meaningful Long-Term Value From Ziihera's Pursuits Beyond GEA, UBS Says

MT Newswires Live
·
Yesterday

Jazz Pharmaceuticals Price Target Raised to $337.00/Share from $315.00 by UBS

Dow Jones
·
Sep 11

UBS Adjusts Jazz Pharmaceuticals PT to $337 From $315, Maintains Buy Rating

MT Newswires Live
·
Sep 11

Jazz Pharmaceuticals Plc : UBS Raises Target Price to $337 from $315

THOMSON REUTERS
·
Sep 11

Jazz Pharma CEO Renee D. Gala Disposes of Ordinary Shares Worth $970,664.07

Reuters
·
Sep 11

Jazz Pharmaceuticals is Maintained at Overweight by Barclays

Dow Jones
·
Sep 10

Jazz Pharmaceuticals Plc : Barclays Raises Target Price to $271 from $270

THOMSON REUTERS
·
Sep 10

Jazz Pharma Director Bruce C. Cozadd Disposes of USD 1.79 Million in Ordinary Shares

Reuters
·
Sep 03

Jazz Pharma Management Joins Wells Fargo Healthcare Conference Fireside Chat

Reuters
·
Sep 03

Why Jazz Pharmaceuticals (JAZZ) Is Down 6.3% After Ziihera’s First-Line HER2-Positive GEA Survival Data And What's Next

Simply Wall St.
·
Sep 02

Jazz Pharma EVP Global Head of R&D and CMO Robert Iannone Disposes of Shares Worth $19.23 Million

Reuters
·
Sep 01

Jazz Pharmaceuticals Unit Launches Private Offering of $1 Billion Exchangeable Senior Notes Due 2032

Reuters
·
Sep 01

Jazz Says FDA Approves Ziihera Combos for First-Line HER2+ Advanced Gastroesophageal Cancer

Reuters
·
Aug 31

Ziihera® (Zanidatamab-Hrii) Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab Plus Chemotherapy in First-Line Her2+ Advanced Gea

THOMSON REUTERS
·
Aug 31

Jazz Pharmaceuticals - Herizon-Gea-01 Results Reinforce Ziihera as Definitive Her2-Targeted Backbone in First-Line Gea

THOMSON REUTERS
·
Aug 31

Jazz Pharmaceuticals - Ziihera U.S. Prescribing Information Contains Boxed Warnings for Diarrhea and Embryo-Fetal Toxicity

THOMSON REUTERS
·
Aug 31

Jazz Pharmaceuticals - Ziihera Plus Tislelizumab and Chemotherapy Improves Os Hazard Ratio, Supporting New Standard of Care

THOMSON REUTERS
·
Aug 31

Jazz Pharmaceuticals: Safety Profile of Ziihera in Combination with Chemotherapy Generally Consistent with Known Safety Profile

THOMSON REUTERS
·
Aug 31

Jazz Pharmaceuticals (JAZZ) Could Be 13% Undervalued On FDA Approval Of Ziihera

Simply Wall St.
·
Aug 30

Jazz Pharmaceuticals Shares May Have Room for Further Appreciation, RBC Says

MT Newswires Live
·
Aug 28